This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PSTI Pluristem Therapeutics (PSTI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pluristem Therapeutics Stock (NASDAQ:PSTI) 30 days 90 days 365 days Advanced Chart Get Pluristem Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.00▼$1.5852-Week Range N/AVolume2,128 shsAverage Volume715,259 shsMarket Capitalization$32.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel. Read More Receive PSTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluristem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTI Stock News HeadlinesNBRVF Nabriva Therapeutics plcAugust 18, 2023 | seekingalpha.comPluri CEO Issues Shareholder UpdateJuly 25, 2022 | finance.yahoo.comChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system tracks breaking AI news and shows when to trade.📈 AI-backed. Beginner-friendly. Results proven.August 2 at 2:00 AM | Timothy Sykes (Ad)Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | benzinga.comPluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional IndustriesJuly 25, 2022 | finance.yahoo.comPluristem (PSTI) Phase III Study Misses Goal, Stock DownJuly 14, 2022 | finance.yahoo.comPluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture SurgeryJuly 13, 2022 | finance.yahoo.comPluristem's Phase 3 Study Of PLX-PAD To Treat Muscle Injury Does Not Meet Primary GoalJuly 13, 2022 | markets.businessinsider.comSee More Headlines PSTI Stock Analysis - Frequently Asked Questions How were Pluristem Therapeutics' earnings last quarter? Pluristem Therapeutics Inc. (NASDAQ:PSTI) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.05. When did Pluristem Therapeutics' stock split? Pluristem Therapeutics's stock reverse split before market open on Thursday, July 25th 2019.The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Pluristem Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pluristem Therapeutics investors own include NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Meta Platforms (META), Gilead Sciences (GILD), Novavax (NVAX) and Alibaba Group (BABA). Company Calendar Last Earnings11/08/2021Today8/01/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PSTI CIK1158780 Webwww.pluristem.com Phone972747107171Fax972-74-710-8787Employees153Year Founded2003Profitability EPS (Trailing Twelve Months)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.87 million Net MarginsN/A Pretax Margin-20,024.79% Return on Equity-100.63% Return on Assets-55.46% Debt Debt-to-Equity Ratio0.57 Current Ratio8.22 Quick Ratio8.22 Sales & Book Value Annual Sales$20 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / BookN/AMiscellaneous Outstanding Shares32,348,000Free Float30,601,000Market Cap$32.35 million OptionableOptionable Beta1.91 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PSTI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluristem Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluristem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.